To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

November 13, 2019

Study Completion Date

January 15, 2020

Conditions
Healthy
Interventions
BIOLOGICAL

CT-P17

40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS

BIOLOGICAL

US-licensed Humira

40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS

BIOLOGICAL

EU-approved Humira

40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS

Trial Locations (9)

13520

CHA Bundang Medical Center, Seongnam-si

13620

Seoul National University Bundang Hospital, Seongnam-si

28644

Chungbuk National University Hospital, Cheongju-si

35015

Chungnam National University Hospital, Daejeon

47392

Inje University Busan Paik Hospital, Busan

54907

Chonbuk National University Hospital, Jeonju

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT03970824 - To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects | Biotech Hunter | Biotech Hunter